R. Hozak

发表

The BIR Motifs Mediate Dominant Interference and Oligomerization of Inhibitor of Apoptosis Op-IAP

G. Manji, R. Hozak, P. Friesen, 2000, Molecular and Cellular Biology.

Baculovirus inhibitor of apoptosis functions at or upstream of the apoptotic suppressor P35 to prevent programmed cell death

D. Lacount, G. Manji, R. Hozak, 1997, Journal of virology.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors

K. Suzukawa, Ling Gao, T. Tamura, 2017, Japanese journal of clinical oncology.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

M. Socinski, R. Kurek, F. Hirsch, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

J. Hainsworth, A. Armstrong, C. Higano, 2015, European journal of cancer.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Joon-Oh Park, R. Greil, E. Van Cutsem, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, European journal of cancer.

O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

J. Ajani, G. Bodoky, Z. Wainberg, 2016 .

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

J. Hainsworth, A. Armstrong, C. Higano, 2016 .

Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).

J. Ajani, C. Fuchs, J. Tabernero, 2015 .

Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

P-C. Yang, Y. Cheng, H. Murakami, 2016 .

Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs.

A. Zimmermann, R. Hozak, M. Irimajiri, 2009, Journal of the American Veterinary Medical Association.

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

J. Ajani, C. Fuchs, J. Tabernero, 2016, British Journal of Cancer.

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

T. Powles, H. Nishiyama, C. Sternberg, 2022, Nature Communications.

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Keunchil Park, D. Planchard, L. Paz-Ares, 2020, Clinical Cancer Research.

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.

Tuan S. Nguyen, Ying Cheng, Pan‐Chyr Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

C. Obasaju, D. Richards, L. Wilfong, 2011, Investigational New Drugs.

Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).

J. Nemunaitis, D. Ferry, L. Gandhi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical field study of the safety and efficacy of spinosad chewable tablets for controlling fleas on dogs.

D. Snyder, A. Zimmermann, R. Hozak, 2008, Veterinary therapeutics : research in applied veterinary medicine.

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

R. Jain, A. Zhu, R. Finn, 2013, Clinical Cancer Research.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

T. Powles, H. Nishiyama, H. Harputluoglu, 2019, The Lancet. Oncology.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

M. Socinski, R. Kurek, F. Hirsch, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

M. Gore, D. Bodurka, U. Matulonis, 2014, Gynecologic oncology.

Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung

T. Holzer, G. Plowman, L. Benjamin, 2013, PloS one.

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

M. Socinski, G. Scagliotti, E. Smit, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Many genomic regions are required for normal embryonic programmed cell death in Caenorhabditis elegans.

W. B. Derry, J. Rothman, J. Zhu, 2001, Genetics.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Tuan S. Nguyen, K. Syrigos, F. Mayer, 2013, Lung cancer.

Kinetics and inhibition of lipid exchange catalyzed by plasma cholesteryl ester transfer protein (lipid transfer protein).

D. Epps, J. Fisher, E. Thomas, 1995, Biochemistry.

Aging and accumulation of microdamage in canine bone.

V. Kalscheur, P. Muir, R. Hozak, 2002, Bone.

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

T. Choueiri, G. Hudes, W. Stadler, 2014, Cancer.

Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study

E. Van Cutsem, J. Tabernero, K. Muro, 2021, Current medical research and opinion.

dad‐1, an endogenous programmed cell death suppressor in Caenorhabditis elegans and vertebrates.

J. Rothman, R. Hozak, A. Sugimoto, 1995, The EMBO journal.

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

M. Gore, D. Bodurka, U. Matulonis, 2014, Gynecologic oncology.